Log in

NASDAQ:CMRX - Chimerix Stock Price, Forecast & News

$1.80
-0.12 (-6.25 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$1.76
Now: $1.80
$2.02
50-Day Range
$1.29
MA: $1.89
$2.72
52-Week Range
$1.25
Now: $1.80
$4.40
Volume1.04 million shs
Average Volume728,673 shs
Market Capitalization$110.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.22 million
Book Value$3.50 per share

Profitability

Net Income$-69,470,000.00
Net Margins-1,162.96%

Miscellaneous

Employees82
Market Cap$110.48 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.


Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.07. The biopharmaceutical company had revenue of $1.96 million for the quarter, compared to analysts' expectations of $1.30 million. Chimerix had a negative net margin of 1,162.96% and a negative return on equity of 38.75%. View Chimerix's Earnings History.

When is Chimerix's next earnings date?

Chimerix is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Chimerix.

What price target have analysts set for CMRX?

3 analysts have issued 12-month price targets for Chimerix's shares. Their forecasts range from $2.00 to $7.00. On average, they expect Chimerix's share price to reach $4.00 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Price Targets for Chimerix.

What is the consensus analysts' recommendation for Chimerix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chimerix.

Has Chimerix been receiving favorable news coverage?

News stories about CMRX stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chimerix earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Chimerix.

Are investors shorting Chimerix?

Chimerix saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 650,100 shares, an increase of 41.8% from the November 14th total of 458,400 shares. Based on an average daily trading volume, of 824,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.4% of the company's stock are short sold. View Chimerix's Current Options Chain.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Wynn Resorts (WYNN), SLS International (SLS), Walmart (WMT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Relypsa (RLYP).

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (5.27%), State Street Corp (1.75%), Man Group plc (0.76%), Millennium Management LLC (0.49%), Russell Investments Group Ltd. (0.21%) and Public Employees Retirement System of Ohio (0.08%). Company insiders that own Chimerix stock include Ernest Mario, Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Institutional Ownership Trends for Chimerix.

Which institutional investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Redmile Group LLC, Millennium Management LLC, State Street Corp and Barclays PLC. View Insider Buying and Selling for Chimerix.

Which institutional investors are buying Chimerix stock?

CMRX stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Public Employees Retirement System of Ohio, Dowling & Yahnke LLC and Meeder Asset Management Inc.. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, M Michelle Berrey, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View Insider Buying and Selling for Chimerix.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $1.80.

How big of a company is Chimerix?

Chimerix has a market capitalization of $110.48 million and generates $7.22 million in revenue each year. The biopharmaceutical company earns $-69,470,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Chimerix employs 82 workers across the globe.View Additional Information About Chimerix.

What is Chimerix's official website?

The official website for Chimerix is http://www.chimerix.com/.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (NASDAQ CMRX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  342 (Vote Underperform)
Total Votes:  670
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel